Clinical Trial Update: Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab as neoadjuvant therapy for locally advanced oral squamous cell carcinoma; currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Prof. Lars Olaf Cardell | Conditions: Oral Squamous Cell Carcinoma (OSCC) | Phase 2 | Status: NOT_YET_RECRUITING